An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)
Latest Information Update: 11 Jun 2024
At a glance
- Drugs NNZ 2591 (Primary)
- Indications Prader-Willi syndrome
- Focus Adverse reactions; Pharmacokinetics
- Acronyms PWS-001
- Sponsors Neuren Pharmaceuticals
- 03 Jun 2024 Status changed from recruiting to discontinued.
- 30 Jun 2023 According to a Neuren Pharmaceuticals media release, the company has been granted Orphan Drug designation by the US Food and Drug Administration (FDA).
- 30 Jun 2023 According to a Neuren Pharmaceuticals media release, results from this trial are expected to follow during 2024.